Maritime Fusion | $4,500,000 | (Nov 25, 2025)
Opti | $20,000,000 | (Nov 25, 2025)
Cordance Medical | $8,000,000 | (Nov 25, 2025)
Certified by Founder
Lodge
DiogenX
start up
France
- Marseille
- 11/05/2023
- Series A
- $30,056,125
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
- Industry Biotechnology
- Website https://diogenx.com/
- LinkedIn https://www.linkedin.com/company/diogenx/
AI One | $7,000,000 | (Nov 25, 2025)
Redrob | $10,000,000 | (Nov 25, 2025)
Pibit.AI | $7,000,000 | (Nov 25, 2025)
Votre | $3,750,000 | (Nov 25, 2025)
Tidalwave | $22,000,000 | (Nov 25, 2025)
Relixir | $2,000,000 | (Nov 25, 2025)
Interface | $3,500,000 | (Nov 25, 2025)
Model ML | $75,000,000 | (Nov 25, 2025)
Mirantus Health | $6,338,062 | (Nov 25, 2025)